• By ICR Secretariat
• Posted Wednesday, May 3, 2023

In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy

https://www.fiercepharma.com/pharma/heavyweight-obesity-fight-lilly-launches-mounjaro-head-head-trial-against-novos-wegovy

The stakes are getting even higher in the fight for supremacy between Eli Lilly and Novo Nordisk in the multibillion-dollar obesity market. Eli Lilly on Friday quietly registered a new phase 3b trial on clinicaltrials.gov.